haematologica
Journal of the Ferrata Storti Foundation

Shedding light on the complicated world of alloreactive NK cells

by Francesco Zorutti, Rebecca Sembenico and Antonio Pierini

Received: October 31, 2025.
Accepted: November 3, 2025.

Citation: Francesco Zorutti, Rebecca Sembenico and Antonio Pierini. Shedding light on the complicated world of alloreactive NK cells.
Haematologica. 2025 Nov 13. doi: 10.3324/haematol.2025.288456 [Epub ahead of print]

Shedding light on the complicated world of alloreactive NK cells

Francesco Zorutti[1], Rebecca Sembenico[1], Antonio Pierini[1]

[1]Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy

Corresponding author:

Antonio Pierini, MD, PhD – e-mail: pierini.antonio@gmail.com

Conflict of Interest

The authors declare that the manuscript was written in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

In this issue, Schäfer and colleagues attempted to evaluate the impact of killer cell immunoglobulin-like receptors (KIR) high-resolution genotyping on outcomes in a large cohort of patients who underwent HLA-matched hematopoietic cell transplantation (HCT) (1). Indeed, they hypothesized that specific donor/recipient KIR/HLA configurations would modify the post-transplant natural killer (NK) cell activation status impacting on transplant outcomes.

To better understand the relevance of their findings it is useful to underline a key principle of donor NK cell functionality in the HCT context: NK cells need to be "educated" by the interaction with self HLA molecules to become fully functional and "educated" NK cells react against allogeneic targets when they lack self-HLA expression. When donor alloreactive NK cells (not inhibited by HLA epitopes) arise from infused donor hematopoietic stem cells after HCT, they can exert a potent antileukemic activity by killing allogeneic leukemic cells. Such event occurs in the presence of specific donor/recipient HLA combinations and was demonstrated to have great clinical impact in T cell depleted HLA-haploidentical HCT in the absence of post-transplant immune suppression (2). In fact, a lower rate of relapse occurred in patients affected by acute myeloid leukemia who received an HLA-haploidentical T cell depleted HCT from a NK cell alloreactive donor. The value of the finding was so high that the possibility to exert NK cell donor alloreactivity became a major criterium for donor selection in T cell depleted HLA-haploidentical transplant setting (3). The effect of alloreactive NK cells was maintained even when donor T cell adoptive immunotherapy was added to the transplant platform as long as no post-transplant immune suppressive drugs were used (4). Furthermore, the role of activatory KIRs has been also studied in T cell depleted HLA-haploidentical transplant setting and a possible impact on viral infectious rate and transplant related mortality (TRM) when specific activating KIR(e.g., KIR2DS1)/HLA interactions occurred has been reported (5).

The discovery of NK cell alloreactivity and the new insights on KIR/HLA interactions paved the way for the development of novel NK cell-based immunotherapies to treat acute leukemia and other cancers (6). Many studies have been of interest and, more recently, engineered chimeric antigen receptor NK cells are under investigation with promising results (7). Unfortunately, to date, none of these treatments reached approval for routine clinical use because of some key limitations such as NK cell number, expansion protocols, in vivo persistence, and killing capacity.

Many attempts have been made to understand whether donor NK cell alloreactivity could be useful in transplant settings other than T-cell depleted HLA-haploidentical transplants, such HLA-matched and unmanipulated transplants. Specific inhibitory or activatory KIR/HLA interactions have been shown to have some impact on major transplant outcomes such as leukemia relapse and survival (8, 9), but conflicting results have been reported and no clear and strong evidence that support routine use of donor KIR genotyping is available to date. In fact, the lack of T-cell depletion and the use of post-transplant immune suppressive agents (e.g., post-transplant cyclophosphamide, PT-Cy), contributed to eliminate alloreactive NK cells in vivo and limited their clinical value (10).

Therefore, because of many transplant-related confounding factors (e.g., donor/recipient HLA-matching, type of conditioning regimen, use of post-transplant immunesuppression), pre-transplant KIR-genotyping is not generally adopted as a valuable tool to predict transplant outcomes and guide clinical choices. Indeed, no link between KIR allelic polymorphism and the level of post-transplant NK cell alloreactivity was clearly found in a large study with more than 5000 transplanted recipients (11).

Another major limitation is the genetic complexity of the KIR system. The number of KIR genes and allelic variations that might occur combined with the lack of sequencing resolution depth are unresolved issues that further challenge its possible routine use. While some beneficial or detrimental effects on HCT outcomes have been associated to selected KIR allele candidates such as KIR3DL1 and KIR2DL1, very few studies investigated the entirety of KIR system in transplant. Today, the advent of easily usable high-resolution genotyping tools might help to overcome such issues.

Applying this modern technology, the present study by Scha□fer and colleagues challenged the hypothesis that specific allelic KIR/HLA configurations would modulate transplant outcomes by predisposing (or not) the patient to donor NK cell alloreactivity in a large retrospective multicentric study of HLA-matched unrelated transplants. The authors demonstrated that post-transplant NK cell alloreactivity was mainly driven by KIR2DS4, KIR2DL2/L3 and KIR3DL1 alleles. They found some relevant effect of specific KIR interactions such as the detrimental effect of KIR2DS4*00101

interactions on survival and TRM and the powerful protection against chronic GvHD in KIR2DL2/L3+ D/R pairs with a missing ligand status. These findings further support the evidence that NK cell mediated alloreactivity protects from the development of chronic GvHD by targeting recipient's dendritic and T cells (2,12). The authors also clarified that activating and inhibitory KIRs do not contribute equally to leukemic control in this setting with findings that largely differ from what has been previously observed in T cell depleted HLA-haploidentical transplants and that remain contradictory and controversial, therefore warranting further investigations.

In conclusion, thanks to the deep analysis and the large data set, the study by Scha□fer and colleagues elucidates important clinical aspects of donor/recipient KIR/HLA interactions in unrelated HLA-matched transplants (Figure 1). In fact, such study does not provide enough evidence to support the use of whole donor KIR genotyping before transplant, but it foresees that a smart sequencing of selected KIR loci would be of great help in unrelated dolor selection, especially when more options are available.

References:

1- Schäfer A, Buhler S, Farias TDJ, et al. Integrating killer cell immunoglobulin-like receptor high-resolution genotyping for predicting transplant outcomes in allogeneic hematopoietic stem cell transplantation. Haematologica. xxx
2- Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002 Mar 15;295(5562):2097-2100.
3- Mancusi A, Ruggeri L, Velardi A. Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation. Blood. 2016;128(23):2616-2623.
4- Pierini A, Ruggeri L, Carotti A, et al. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv. 2021;5(5):1199-1208.
5- Mancusi A, Ruggeri L, Urbani E, et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality Blood. 2015;125(20):3173-3182.
6- Ruggeri L, Parisi S, Urbani E, et al. Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy. Front Immunol. 2015;6:479.
7- Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553.
8- Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419.
9- Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol. 2014;192(10):4592-4600.
10- Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247-262.
11- Schetelig J, Baldauf H, Heidenreich F, et al. Donor *KIR* genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. Front Immunol. 2024;15:1350470.
12- Garrod KR, Liu FC, Forrest LE, et al. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. J Immunol. 2010;184(5):2329-2336.

Figure Legend

A schematic representation of suggested unrelated donor selection through KIR genotyping. KIR genotyping of HLA-matched unrelated donors informs about inhibitory and activatory KIRs that can interact with recipient HLA molecules. Specific KIR/HLA interactions might help to predict probability of some transplant outcomes such as chronic GvHD and overall survival. This information could help to improve unrelated donor selection.


HLA-Matched unrelated donors
KIR Genotyping
INIB
ACT
KIRs
KIRs interaction with recipient HLA
A donor that possibly ensures
• Less cGvHD (No KIR2DL2 and KIR2DL3 - HLA C1 interactions?)
• Less relapse (No KIR3DL1 interactions?)
• Better overall survival (No KIR2DS4*00101 interactions?)